by Alex Kadhim
Researchers identified a subset of glioblastomas with high levels of tumor-infiltrating lymphocytes (TIL) that contained clonally expanded, exhausted CD8⁺ T cells marked by LAG3, suggesting the...
by Alex Kadhim
Researchers found that malignant pleural effusion (MPE) may serve as a minimally invasive source of tumor-reactive T cells for tumor-infiltrating lymphocyte (TIL) therapy. Compared with surgically...
by ASTCT Talks
In this episode of ASTCT Talks, host Daniel Olson, MD, medical oncologist and co-leader of the melanoma, sarcoma, and solid tumor cellular therapy programs at the University of Chicago, is joined...
by Alex Kadhim
Analysis drawing on tumor-infiltrating lymphocyte (TIL) therapy performed at Memorial Sloan Kettering Cancer Center in New York, with collaboration at Weill Cornell Medical College and Stanford...
by Alex Kadhim
A case report from the University of Kansas Medical Center highlights how a documented drug intolerance mislabeled as an allergy can leave a profoundly immunosuppressed cancer patient without...
by Alex Kadhim
Researchers identified ADGRG1 and CD86 as novel markers of tumor-reactive CD4+ T cells in solid tumors, enabling enrichment of neoantigen-specific lymphocytes for functional studies and...